A team of professors and students from the Indian Institute of Technology Delhi has been working on to make life-saving biotech drugs affordable. With this technology, the manufacturing cost of the biotech drugs can be reduced. At present, the manufacturing cost itself is 30% of total cost borne by the drug makers. The IIT team proposes to encourage more companies interested in entering the biotherapeutics space by drastically reducing the cost of manufacturing these medicines by increasing the competition. The team has figured out how to continuously churn out medicines, a process that could cut the cost of manufacturing certain types of biologic drugs by as much as 70%. The team developed a sampling device that can be installed throughout the system as well as an online tool that would cut down the time taken to analyse each sample for impurities to as little as four minutes from 30 to 70 minutes without any need for manual intervention. The team is also trying to develop technology to continuously manufacture monoclonal antibodies such as trastuzumab and bevacizumab that stimulate the patient’s immune system to attack specific kinds of antigens, including cancer cells. Biotech drugmakers like the Bengaluru-based Biocon and US-based Paul Life Sciences along with some government departments, have given IIT 15 crore to reconstruct its tiny prototype in a 1,600 square-foot lab on campus.